2010Zhongguo yaofangRequires access

Analysis on Clinical Efficacy and Safety of Pioglitazone Combined with Metformin in the Treatment of Type 2 Diabetes

Wei-Ying Guo

Open publisher page 1 citations

Abstract

OBJECTIVE:To analyze clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes.METHODS:102 patients with type 2 diabetes were randomly divided into 2 groups.Treatment group received pioglitazone combined with metformin and treatment group received metformin alone.The levels of blood glucose and insulin were observed and compared between 2 groups.RESULTS:After 6 months of treatment,fasting plasma glucose(FPG),postprandial 2 h blood glucose(P2hBG),glycosylated hemoglobin(HbA1c),fasting insulin(FINS),postprandial 2 h insulin(P2hINS),steady-state assessment index of insulin(HOMA-IR) in 2 groups were significantly decreased,there was statistical significance in difference before and after treatment(P0.05).After treatment,the level of FPG,P2hBG,HbA1c,FINS,P2hINS and HOMA-IR in treatment group was significantly lower than in control group,there was statistical significance(P0.05);There were few adverse drug reactions,and no serious adverse drug reaction was observed.CONCLUSION:Pioglitazone combined with metformin can significantly lower the level of blood sugar and improve insulin index in patients with type 2 diabetes with few adverse drug reactions.

About this research paper

What this paper is about

OBJECTIVE:To analyze clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes.METHODS:102 patients with type 2 diabetes were randomly divided into 2 groups.Treatment group received pioglitazone combined with metformin and treatment group received metformin alone.The levels of blood glucose and insulin were observed and compared between 2 groups.RESULTS:After 6 months of treatment,fasting plasma glucose(FPG),postprandial 2 h blood glucose(P2hBG),glycosylated hemoglobin(HbA1c),fasting insulin(FINS),postprandial 2 h insulin(P2hINS),steady-state assessment index of insulin(HOMA-IR) in 2 groups were significantly decreased,there was statistical significance in difference before and after treatment(P0.05).After treatment,the level of FPG,P2hBG,HbA1c,FINS,P2hINS and HOMA-IR in treatment group was significantly lower than in control group,there was statistical significance(P0.05);There were few adverse drug reactions,and no serious adverse drug reaction was observed.CONCLUSION:Pioglitazone combined with metformin can significantly lower the level of blood sugar and improve insulin index in patients with type 2 diabetes with few adverse drug reactions.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE:To analyze clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes.METHODS:102 patients with type 2 diabetes were randomly divided into 2 groups.Treatment group received pioglitazone combined with metformin and treatment group received metformin alone.The levels of blood glucose and insulin were observed and compared between 2 groups.RESULTS:After 6 months of treatment,fasting plasma glucose(FPG),postprandial 2 h blood glucose(P2hBG),glycosylated hemoglobin(HbA1c),fasting insulin(FINS),postprandial 2 h insulin(P2hINS),steady-state assessment index of insulin(HOMA-IR) in 2 groups were significantly decreased,there was statistical significance in difference before and after treatment(P0.05).After treatment,the level of FPG,P2hBG,HbA1c,FINS,P2hINS and HOMA-IR in treatment group was significantly lower than in control group,there was statistical significance(P0.05);There were few adverse drug reactions,and no serious adverse drug reaction was observed.CONCLUSION:Pioglitazone combined with metformin can significantly lower the level of blood sugar and improve insulin index in patients with type 2 diabetes with few adverse drug reactions.

Key concepts: Pioglitazone, Postprandial, Metformin, Medicine, Internal medicine, Type 2 diabetes, Insulin, Adverse effect

Related papers

Back to paper searchBrowse research topicsOriginal source
Analysis on Clinical Efficacy and Safety of Pioglitazone Combined with Metformin in the Treatment of Type 2 Diabetes — Research Paper | ScholarLens